Skip to main content
BBIXF logo

Bonus BioGroup Ltd. (BBIXF) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.04 $0.00 (0.00%)
MCap: $46.7M| Vol: 10.0K|

Market cap $46.7M is the value of all shares combined. Beta 0.81: the stock has moved about 19% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Bonus BioGroup Ltd. (BBIXF) trades at $0.04. Bonus BioGroup Ltd. is a biotechnology company focused on developing tissue-regenerating bone grafts for skeletal disorders. Market cap: $46.7M, Sector: Healthcare.

Price as of · Last analyzed: Mar 17, 2026
Bonus BioGroup Ltd. is a biotechnology company focused on developing tissue-regenerating bone grafts for skeletal disorders. Their technology utilizes a patient's own cells to create bone grafts for various orthopedic and maxillofacial applications.

Analyst Coverage for BBIXF: BBIXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Bonus BioGroup Ltd. (BBIXF) Healthcare & Pipeline Overview

CEOShai Meretzki
Employees42
HeadquartersHaifa, IL
IPO Year2019

Bonus BioGroup Ltd., based in Israel, is a biotechnology firm specializing in autologous cell-based bone regeneration technologies. Their focus on personalized bone grafts for skeletal disorders positions them in the regenerative medicine sector, with products targeting bone trauma, arthritis, and large bone defects.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for BBIXF?

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Bonus BioGroup presents a compelling, albeit high-risk, investment thesis centered on its autologous bone regeneration technology. The company's BonoFill products address a significant market need for personalized bone grafts, potentially reducing complications associated with traditional allografts. Key value drivers include successful clinical trials demonstrating the efficacy of BonoFill in treating skeletal disorders, regulatory approvals in key markets, and strategic partnerships for commercialization. However, the company's negative P/E ratio of -11.72 reflects its current lack of profitability, and the relatively low beta of 0.81 suggests lower volatility compared to the broader market. Growth catalysts include the advancement of its pipeline products, particularly the large vascularized bone grafts, and expansion into new geographic markets. The investment thesis hinges on Bonus BioGroup's ability to successfully navigate the regulatory landscape, secure funding for ongoing research and development, and effectively commercialize its products.

Based on FMP financials and quantitative analysis

BBIXF Key Highlights

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $46.7M reflects the company's current valuation in the biotechnology sector.

  • A P/E ratio of -11.72 indicates that the company is currently not profitable, common for biotechnology firms in the development stage.
  • The company employs 49 individuals, suggesting a focused and lean operational structure.
  • Development of BonoFill injectable bone graft targets a specific need in bone repair applications, including jaw bone cysts.
  • Pipeline includes bone grafts for maxillofacial and orthopedic applications, indicating potential for future growth.

Who Are BBIXF's Competitors?

BBIXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CLCS Cell Source, Inc. $0.43 0.00% $29.2M —
CLIFF Cordlife Group Limited $0.13 0.00% $32.9M —
CLYYF Celyad Oncology S.A. $0.28 0.00% $21.0M —
ELVAF EvoNext Holdings S.A. $2.15 0.00% $15.5M —
FNCH Finch Therapeutics Group, Inc. $10.20 +0.99% $16.4M —
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BBIXF's Key Strengths?

Proprietary autologous cell-based bone regeneration technology.

  • BonoFill products offer a personalized approach to bone repair.
  • Focus on addressing unmet needs in skeletal disorders.
  • Pipeline of innovative bone graft products.

What Are BBIXF's Weaknesses?

Limited commercialization experience.

  • Reliance on regulatory approvals for product launches.
  • High research and development costs.
  • Negative P/E ratio indicates current lack of profitability.

What Could Drive BBIXF Stock Higher?

Clinical trial results for BonoFill in new orthopedic applications.

  • Regulatory approvals for BonoFill in the United States and Europe.
  • Development of novel nanomaterials technology for tissue regeneration.
  • Advancement of large vascularized bone grafts.
  • Strategic partnerships for commercialization.

What Are the Key Risks for BBIXF?

Financial-distress signal — its Altman Z-Score of -39.60 sits in the distress zone (elevated bankruptcy risk).

  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Competition from established bone graft companies.
  • Regulatory hurdles and delays in product approvals.
  • Technological advancements in alternative bone regeneration methods.
  • High research and development costs.
  • Reliance on regulatory approvals for product launches.

What Are the Growth Opportunities for BBIXF?

  • Expansion of BonoFill product line: Bonus BioGroup has the opportunity to broaden the applications of its BonoFill injectable and pre-designed bone grafts. Targeting specific orthopedic procedures, such as spinal fusion or joint reconstruction, could significantly increase market penetration. The global bone graft market is projected to reach $6.2 billion by 2027, offering a substantial addressable market. Success will depend on clinical data supporting efficacy in these new applications and securing regulatory approvals.
  • Development of novel nanomaterials technology: The company's research into nanomaterials for tissue regeneration presents a significant growth opportunity. Nanomaterials can enhance bone regeneration by providing a scaffold for cell attachment and promoting angiogenesis. The market for nanomaterials in regenerative medicine is expected to grow rapidly, driven by advancements in materials science and nanotechnology. Successful development and commercialization of nanomaterial-based bone grafts could provide Bonus BioGroup with a competitive advantage and access to a high-growth market segment.
  • Advancement of large vascularized bone grafts: The development of large vascularized bone grafts represents a significant advancement in bone regeneration. These grafts have the potential to address large bone defects and improve outcomes in complex orthopedic procedures. The market for vascularized bone grafts is currently limited but is expected to grow as the technology matures and clinical evidence accumulates. Bonus BioGroup's expertise in cell-based therapies positions it to capitalize on this emerging market opportunity.
  • Strategic partnerships for commercialization: Forming strategic partnerships with established orthopedic companies or distributors can accelerate the commercialization of Bonus BioGroup's products. These partnerships can provide access to established sales channels, marketing expertise, and regulatory support. The global orthopedic market is dominated by a few large players, and partnering with one of these companies could significantly increase Bonus BioGroup's market reach and revenue potential. Successful partnerships will depend on demonstrating the clinical and economic value of Bonus BioGroup's products.
  • Geographic expansion into new markets: Expanding into new geographic markets, such as the United States and Europe, represents a significant growth opportunity for Bonus BioGroup. These markets have a large and growing demand for bone grafts, driven by the aging population and the increasing prevalence of skeletal disorders. However, entering these markets requires significant investment in regulatory approvals, clinical trials, and marketing. Bonus BioGroup will need to carefully assess the market potential and develop a comprehensive market entry strategy to succeed in these new geographies.

What Are BBIXF's Competitive Advantages?

  • Proprietary autologous cell-based technology.
  • Patented BonoFill bone graft products.
  • Expertise in tissue regeneration and bone engineering.
  • Focus on personalized medicine approach.

What Does BBIXF Do?

Founded in 1981 as Oceana Advanced Industries Ltd. and later rebranded as Bonus BioGroup Ltd., the company is dedicated to developing and commercializing advanced tissue-regenerating bone grafts. Their core technology centers around creating bone grafts from a patient's own cells, minimizing the risk of rejection and promoting faster healing. The company's flagship products include BonoFill injectable bone graft, designed for applications like jaw bone cysts, and BonoFill pre-designed bone graft, intended for repairing large and segmental bone defects. These products address a significant need in the treatment of skeletal disorders, offering a personalized approach to bone regeneration. Bonus BioGroup's pipeline includes bone grafts for maxillofacial and orthopedic applications, novel nanomaterials technology for tissue regeneration, and large vascularized bone grafts, indicating a commitment to expanding its product portfolio and addressing a broader range of clinical needs. Headquartered in Haifa, Israel, Bonus BioGroup is focused on advancing its technology and securing regulatory approvals to bring its innovative bone regeneration solutions to market.

What Products and Services Does BBIXF Offer?

  • Develops tissue-regenerating bone grafts using a patient's own cells.
  • Offers BonoFill injectable bone graft for bone repair applications.
  • Provides BonoFill pre-designed bone graft for large and segmental bone defects.
  • Focuses on treating skeletal disorders like bone trauma and arthritis.
  • Researches novel nanomaterials technology for tissue regeneration.
  • Develops large vascularized bone grafts for complex bone defects.

How Does BBIXF Make Money?

  • Develops and manufactures autologous bone grafts.
  • Commercializes bone grafts through direct sales or partnerships.
  • Generates revenue from the sale of BonoFill products.
  • Invests in research and development to expand its product pipeline.

What Industry Does BBIXF Operate In?

The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant capital requirements. The market for bone grafts is driven by the increasing prevalence of skeletal disorders, trauma, and the aging population. Bonus BioGroup operates in the regenerative medicine segment, which is experiencing rapid growth due to advancements in cell-based therapies and personalized medicine. The competitive landscape includes companies developing synthetic bone grafts, allografts, and other regenerative technologies. Key trends include the shift towards minimally invasive procedures, the demand for biocompatible materials, and the focus on personalized treatment approaches. Bonus BioGroup's autologous cell-based technology positions it to capitalize on the trend towards personalized medicine in bone regeneration.

Who Are BBIXF's Key Customers?

  • Orthopedic surgeons
  • Maxillofacial surgeons
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 17, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage

How Bonus BioGroup Ltd. Is Valued

Bonus BioGroup Ltd. carries a market capitalization of $46.7M, placing it in the micro-cap category.

Company Profile

Bonus BioGroup Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Haifa, Israel.

ROE 337%

Key Financial Metrics

Return on equity for Bonus BioGroup Ltd. stands at 337.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -8.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -12.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9

Financial Health

Bonus BioGroup Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.60 places it in the distress zone, a signal of elevated financial risk.

BBIXF Financials

Bull Case vs Bear Case

Bull Case

  • Proprietary autologous cell-based bone regeneration technology.
  • BonoFill products offer a personalized approach to bone repair.
  • Focus on addressing unmet needs in skeletal disorders.
  • Pipeline of innovative bone graft products.

Bear Case

  • Limited commercialization experience.
  • Reliance on regulatory approvals for product launches.
  • High research and development costs.
  • Negative P/E ratio indicates current lack of profitability.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

BBIXF Latest News

No recent news available for BBIXF.

BBIXF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BBIXF.

Price Targets

Wall Street price target analysis for BBIXF.

BBIXF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BBIXF; grades run from A+ (80-100) to F (below 30).

Leadership: Shai Meretzki

CEO

Shai Meretzki serves as the CEO of Bonus BioGroup Ltd. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions in various companies, focusing on business development, strategic planning, and product commercialization. Meretzki's expertise spans across multiple therapeutic areas, including regenerative medicine and cell-based therapies. He is responsible for driving Bonus BioGroup's strategic vision and overseeing the company's research and development efforts.

Track Record: Under Shai Meretzki's leadership, Bonus BioGroup has focused on advancing its BonoFill product line and expanding its pipeline of bone graft products. Key milestones include securing regulatory approvals for BonoFill in select markets and initiating clinical trials for new applications. Meretzki has also overseen the company's efforts to develop novel nanomaterials technology for tissue regeneration and large vascularized bone grafts. His strategic decisions have been instrumental in positioning Bonus BioGroup as a leader in autologous cell-based bone regeneration.

BBIXF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Bonus BioGroup (BBIXF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to limited regulatory oversight and may not be required to provide audited financial statements. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ, as the availability of information and regulatory scrutiny are significantly reduced.

  • OTC Tier: OTC Other
Liquidity: Liquidity for BBIXF on the OTC market is likely to be limited, given its listing on the OTC Other tier. This typically translates to lower trading volumes and wider bid-ask spreads compared to stocks listed on major exchanges. Investors may experience difficulty buying or selling shares at desired prices, particularly in large quantities. The lack of liquidity can also increase price volatility and make it more challenging to exit a position quickly.
OTC Risk Factors:
  • Limited regulatory oversight and disclosure requirements on the OTC Other tier.
  • Potential for price manipulation due to low trading volumes.
  • Higher risk of fraud or misrepresentation compared to major exchanges.
  • Difficulty in obtaining accurate and timely financial information.
  • Limited liquidity and wider bid-ask spreads.
Due Diligence Checklist:
  • Verify the company's financial statements and audit reports.
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's regulatory compliance and legal standing.
  • Determine the company's capital structure and funding sources.
  • Analyze the company's market capitalization and trading volume.
  • Consult with a qualified financial advisor.
Legitimacy Signals:
  • Development of proprietary autologous cell-based bone regeneration technology.
  • Focus on addressing unmet needs in skeletal disorders.
  • Pipeline of innovative bone graft products.
  • Experienced management team with expertise in biotechnology.
  • Scientific publications or presentations supporting the efficacy of BonoFill products.

What Investors Ask About Bonus BioGroup Ltd. (BBIXF) — Healthcare

Is BBIXF a good stock to buy?

Stock Expert AI does not rate BBIXF buy, sell or hold. Bonus BioGroup Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BBIXF stock price today?

The last price recorded on this page for Bonus BioGroup Ltd. (BBIXF) is $0.04, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Bonus BioGroup Ltd. do?

Bonus BioGroup Ltd. is a biotechnology company specializing in the development of tissue-regenerating bone grafts. Their core technology revolves around creating personalized bone grafts from a patient's own cells, which minimizes the risk of rejection and promotes faster healing.

What are the key factors to evaluate for BBIXF?

Evaluate BBIXF on fundamentals, analyst consensus, and risk factors. Development of BonoFill injectable bone graft targets a specific need in bone repair applications, including jaw bone cysts. Not financial advice.

How frequently does BBIXF data refresh on this page?

BBIXF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BBIXF's recent stock price performance?

Bonus BioGroup Ltd. (BBIXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary autologous cell-based bone regeneration technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BBIXF overvalued or undervalued right now?

Bonus BioGroup Ltd. (BBIXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research BBIXF before investing?

Before investing in Bonus BioGroup Ltd. (BBIXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited analyst coverage for BBIXF may impact the accuracy of some data.
  • OTC market investments carry higher risks than exchange-listed stocks.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives